Heart pump may help High-Risk patients get Life-Saving artery treatment

NCT ID NCT07678021

First seen Jul 01, 2026 · Last updated Jul 01, 2026

Summary

This study tests whether using a temporary heart pump (CorVad) during a procedure to open blocked arteries (PCI) can improve outcomes for people with complex coronary artery disease and a very weak heart (ejection fraction below 35%). Half of the 452 participants will receive the pump-assisted PCI plus standard medications, while the other half will receive medications alone. The main goal is to see if the pump reduces major heart and brain events like death, heart attack, stroke, or heart failure readmission over one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CorVad micro-axial flow pump (device) and optimal medical therapy (drugs)

What this could lead to

If successful, this approach could offer a safer way to open blocked arteries in people with severely weakened hearts, potentially reducing heart attacks, strokes, and hospitalizations.

What could go wrong

This is a mid-stage trial with 452 participants, so results may not apply to everyone. The pump procedure carries risks like bleeding, hemolysis, or stent complications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE (CAD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder left ventricular failure Ventricular Dysfunction, Left

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, 100037, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact